ALK is currently testing its tablet against house dust mite allergies in children in a large phase III study taking place across the US and Europe. The company finished enrollment earlier this year – and among the patient population are people from Ukraine and Russia.
In connection with ALK’s recently publicized financial report, it was stated that the number of people who had had to leave the trial due to the ongoing war in Ukraine was minimal.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
FDA fast-tracks Eli Lilly's obesity candidate
Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.
Jefferies spots weaknesses in GN
One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.
Bavarian initiates new arm of phase III Covid-19 vaccine trial
The first patient has already been dosed in the US, and the Danish vaccine maker is now expanding the study to include Denmark and Belgium.
Life science CEOs' paychecks decrease as markets decline
When the markets are down, everyone is in the same boat, in theory -- however, former Ambu CEO Lars Marcher warns boards against unduly rewarding CEOs by changing pre-existing share-based programs.
Fujifilm doubles bottom line in annual report
Despite a 12.5% cost increase compared to the preceding year, Fujifilm Diosynth Biotechnologies managed to increase its profit twofold in 2021/2022.
Lab Manager 
Manager for Process Support - 1st line support 
Quality Assurance & Regulatory Affairs Manager 
KLIFO is looking for a Compliance Coordinator for our Glostrup office 
Principal Scientist - Drug Metabolism & Pharmacokinetics 
Pharmacovigilance & Regulatory Assistant with an interest in non-fiction 
Clinical Project Lead 
Nordic Key Account Manager, Hollister & Dansac 
Experienced Medical Device Developer 
Senior CMC Regulatory Manager 
Senior Manager, QA GMP 
Chief Business Officer 
Scientist Radiochemistry 
Senior/lead consultant at Emendo Engineering